Drugs in MeSH Category Oxidants

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Aclaris	ESKATA	hydrogen peroxide	SOLUTION;TOPICAL	209305-001	Dec 14, 2017		DISCN	Yes	No	10,098,910		Y
Aclaris	ESKATA	hydrogen peroxide	SOLUTION;TOPICAL	209305-001	Dec 14, 2017		DISCN	Yes	No	10,493,103		Y
Aclaris	ESKATA	hydrogen peroxide	SOLUTION;TOPICAL	209305-001	Dec 14, 2017		DISCN	Yes	No	9,675,639		Y
Aclaris	ESKATA	hydrogen peroxide	SOLUTION;TOPICAL	209305-001	Dec 14, 2017		DISCN	Yes	No	10,729,720		Y
Aclaris	ESKATA	hydrogen peroxide	SOLUTION;TOPICAL	209305-001	Dec 14, 2017		DISCN	Yes	No	9,980,983

Patent Landscape and Market Dynamics for Drugs in NLM MeSH Class: Oxidants

Last updated: July 29, 2026

Executive summary

NLM MeSH “Oxidants” is a cross-cutting umbrella that spans chemotherapeutic oxidants, antimicrobial oxidants, ophthalmic oxidative-therapy agents, dental/periodontal oxidizers, and industrial-strength oxidizing actives repurposed for medical use. The patent landscape is dominated by (1) formulation and concentration/vehicle patents for topical/ocular uses, (2) manufacturing-process and stability patents for reactive oxidants, and (3) method-of-use claims tied to specific disease states or treatment regimens. Patent expiry and exclusivity are uneven because many “oxidants” are older actives with modern second-generation patents on delivery systems, dosing schedules, or combination regimens. Market dynamics are likewise fragmented: hospital and specialty distribution for oncology/antimicrobial oxidants, versus lower-margin recurring use for oral/dental and ophthalmic oxidative-care products, with higher switching cost where clinicians follow product-specific protocols.

How do NLM MeSH Class “Oxidants” drugs differ by mechanism and IP strategy?

MeSH “Oxidants” aggregates agents that create oxidative stress, act as oxidizing reagents directly, or deliver oxidant species (eg, reactive oxygen species precursors/targets). For patent analytics, the key segmentation is whether the oxidant’s novelty is chemistry-first (new oxidant active) or delivery-first (new regimen, formulation, or device).

Oxidant categories that drive separate patent buckets

Direct oxidizing agents (reactive small molecules)

• Patent focus: formulation stability (light/heat/oxygen), controlled release, encapsulation, and preservative systems that prevent premature decomposition.
• Typical claim themes: “a stable composition comprising …” plus process claims for maintaining oxidant potency.

Oxidant-generating therapies (prodrugs or systems that form oxidants in situ)

• Patent focus: activation mechanism, dosing triggers, and patient selection (lesion/compartment specificity).
• Typical claim themes: method-of-use tied to target tissue and local oxidative generation.

Oxidative-antimicrobial or oxidative wound-care agents

• Patent focus: local concentration, contact time, and carrier/vehicle compatibility with wound environments.
• Typical claim themes: treatment of infected tissue, biofilm reduction, or prevention of colonization with specific administration steps.

Why the oxidant label creates licensing and litigation patterns

Oxidants often face “functional” obviousness arguments because the therapeutic effect is tied to oxidative reactivity rather than unique molecular structure. As a result, modern patent estates skew toward:

• formulation parameters (pH, solvents, viscosity, osmolarity, stabilizers)
• storage and shelf-life constraints
• combination regimens with adjunct agents (buffering systems, antimicrobials, antibiotics, surfactants)
• device-mediated dosing (delivery systems that regulate release and contact time)

What patents protect oxidant drugs most often: formulations, methods of use, or manufacturing?

For MeSH “Oxidants,” the dominant protection pattern is secondary IP around “how the oxidant is delivered and used,” not just “what oxidant exists.” That includes:

• formulation and composition claims
• device and delivery-system claims
• process and stability claims
• method-of-use claims

Formulation patents: concentration and stability dominate

Common claim motifs in oxidant estates include:

• stable aqueous formulations with specified concentration ranges
• stabilizers/chelators/antioxidant protectants that slow decomposition without impairing local action
• pH and ionic strength limits to preserve oxidative capacity until administration
• osmolarity/viscosity ranges for ocular and mucosal products

Method-of-use patents: disease-state targeting and regimen construction

Oxidants frequently get later patents on:

• specific indications (eg, refractory infections, oxidative-stress-related conditions, ocular surface disease categories)
• dosing regimens (frequency and duration)
• sequence of administration (contact time or staged therapy)

Manufacturing patents: reactive-spec handling and quality control

Because oxidants are reactive, manufacturing patents typically claim:

• controlled-temperature synthesis or formulation steps
• oxygen exclusion and packaging systems
• analytical release criteria linked to oxidant potency measures

When do oxidant drugs lose exclusivity, and what drives early versus late entry?

Exclusivity timing in oxidants is driven by two factors:

1. whether the drug is older (composition-of-matter already expired) and later patents are “evergreening”
2. the regulatory pathway (Rx NDA/505(b)(1) vs OTC, ophthalmic 505(b)(1), or device-combined products)

Typical exclusivity mechanics relevant to oxidants

• Orphan exclusivity can extend exclusivity for small-population oxidative therapies tied to oncology.
• New chemical entity (NCE) / new molecular entity (NME) exclusivity applies if the active oxidant is newly approved.
• Oral/topical/ocular combination strategies often route through 505(b)(1), where exclusivity may attach to formulation change rather than the base active.

Practical patent-expiry pattern

• First-generation approvals often have expired composition-of-matter by now.
• Current market competition is frequently shaped by:
  • formulation patents with later filing dates
  • method-of-use patents that cover narrow regimens
  • packaging or device patents that are difficult to design around

What generic entry risks exist for oxidant drugs under Paragraph IV?

Paragraph IV risk in oxidants tends to be higher where the listed Orange Book patents include:

• narrow formulation claims with defined concentration ranges
• stability/packaging method claims tied to shelf-life
• method-of-use patents that are still in force for current indications

Design-around feasibility is often constrained by reactivity

In practice, generic sponsors must preserve:

• oxidative potency at administration time
• stability through shelf-life
• compatibility with the chosen vehicle and route

That makes design-around more complex than for non-reactive small molecules, even when the active is “chemically known.”

How strong is the patent estate for oxidants: what claim types survive litigation most often?

In oxidants, claim strength is usually concentrated in:

• formulation claims with explicit numerical ranges
• method-of-use claims tied to clinical steps and endpoints
• manufacturing/process claims with enforceable control parameters

Litigation posture that commonly appears

• If composition-of-matter is expired, brand protection relies on “use” and “formulation” patents.
• Generics often challenge validity based on obviousness or lack of written description for narrow numeric ranges.
• Brands typically enforce with injunction threats tied to current labeling use.

What is the Orange Book status of oxidant drugs, and how many listed patents typically block generic entry?

The Orange Book status is product-specific, but the pattern across oxidant categories is consistent:

• multiple listed patents per product, with at least one formulation-related patent and at least one method-of-use patent when the brand pursued lifecycle management
• late-added patents can persist on the Orange Book for years if linked to post-approval changes or new labeling indications

How to interpret Orange Book listings for oxidants

• A product with many formulation/method-of-use patents still may be vulnerable if claim scope is narrow and can be avoided by changing concentration ranges or dosing regimen.
• A product with active manufacturing/stability claims can be harder for generics to “switch around,” because stability and potency have to be preserved to meet quality requirements.

Which companies are challenging or defending oxidant patents most often?

Oxidant challenges are typically filed by:

• established generic players for mature actives with expired composition-of-matter
• specialty generics for ophthalmic and topical products where formulation is the main moat
• “Section viii” challengers and label-changers aiming to avoid method-of-use claim coverage by altering labeling

Brand defense often involves:

• enforcing “current labeling” tied to method-of-use patents
• asserting formulation patents in parallel across multiple generics or multiple NDCs within the same product family

How do biosimilar risks apply to “oxidants”?

Most MeSH oxidants are small molecules or reactive agents and do not map cleanly to biologics and biosimilar frameworks. Biosimilar risk is usually not the core issue unless a particular oxidant product is tied to a biologic-based oxidative system (rare for MeSH oxidants).

How do oxidant drugs compare with other MeSH categories in patent density and lifecycle strategy?

Compared with classic small-molecule chronic therapies, oxidants show:

• higher dependence on formulation and regimen patents
• more frequent lifecycle management through vehicle changes, stability/preservation system updates, and route-specific improvements
• narrower, label-tied method-of-use protection

This shifts the market competition from “active ingredient” competition to “product performance and labeling compliance” competition.

What formulations are protected by oxidant patents: ocular, dental, topical, or parenteral?

Across the oxidant class, the formulation moat is most visible in:

• Ocular oxidants: vehicle and osmolarity/viscosity, pH constraints, preservative compatibility, and light-protection packaging.
• Topical wound/skin oxidative therapies: solvent system, contact-time engineering, and stability in the presence of biological fluids.
• Dental/periodontal oxidants: delivery vehicles that maintain oxidizing activity in the oral environment (saliva and enzymatic degradation).
• Parenteral oxidant therapies: stability and infusion compatibility to preserve potency and avoid premature decomposition.

What patent litigation affects oxidant drug sales most: injunctions, settlements, or consolidated defenses?

Oxidant litigation tends to produce business outcomes via:

• Partial stays tied to design-around and labeling commitments
• Multi-NDC settlement packages where generics agree to delay launch on specific strengths or dosage forms
• Consolidated discovery focusing on stability and potency measurement, which is central to oxidant formulations

Because oxidants are sensitive to storage and handling, damages and injunction leverage frequently hinge on whether the generic can meet potency specifications over the shelf-life period, not just chemical identity.

What settlement agreements typically appear in oxidant disputes?

Settlement patterns vary by product, but common business terms include:

• launch timing delays on the challenged patents
• carve-outs for unapproved strengths or alternative formulations not covered by the settlement
• labeling commitments that avoid method-of-use claims
• agreements on product substitutions (eg, switching a generic’s vehicle or concentration to reduce infringement exposure)

When do oxidant generic launches occur relative to FDA review milestones?

Launch timing for oxidants often aligns with:

• the ability to secure FDA approval with stability and potency test data
• the resolution of patent disputes impacting the Orange Book-listed patents for the labeled indications
• any agreed labeling changes in settlements

Even when FDA approval is granted, market launch can be delayed by remaining exclusivity or patent injunction risk.

How does the competitive landscape look for oxidant therapies: hospital pull-through vs outpatient substitution?

The competitive landscape depends on use setting:

• Hospital/outpatient oncology or inpatient antimicrobial oxidant use: clinicians follow protocol; formularies matter; brand switching is slower where administration protocols are standardized.
• Ophthalmic and topical outpatient oxidative products: retail and specialty pharmacy substitution is faster but constrained by NDC-level formulation equivalence and labeling.
• Dental/oral oxidative products: switching is often tied to provider preference and performance perception; brands invest in chairside protocol and packaging differentiation.

Key Takeaways

• Patent estates in NLM MeSH “Oxidants” are dominated by formulation, stability, and regimen-specific method-of-use claims, not only active-ingredient chemistry.
• Generic entry risk under Paragraph IV is elevated when Orange Book listings include narrow concentration/vehicle claims and label-tied method-of-use patents.
• Exclusivity timing is uneven; current competition is often determined by lifecycle-managed patents rather than original composition-of-matter expiration.
• Litigation leverage frequently turns on stability and potency preservation through shelf-life and on labeling compliance with method-of-use claims.
• Competitive dynamics split by setting: hospital protocols slow switching; outpatient ocular/topical use drives NDC-specific substitution and formulation scrutiny.

FAQs

1. Which patent claim types most restrict generic versions of reactive oxidant drugs?
2. How do stability and potency testing requirements affect ANDA/505(b)(2) product development for oxidants?
3. What Orange Book listing patterns indicate method-of-use risk for oxidant products?
4. Do oxidant lifecycle patents typically cover multiple indications or only narrow label subsets?
5. What design-around strategies are most common for oxidant formulations without losing oxidative efficacy?

References

1. National Library of Medicine. MeSH Browser. “Oxidants.”
2. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.